发明授权
US08293913B2 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor
有权
喹啉化合物适用于治疗对血清素-5-HT6受体调节作用的疾病
- 专利标题： Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin-5-HT6 receptor
- 专利标题（中）： 喹啉化合物适用于治疗对血清素-5-HT6受体调节作用的疾病
-
申请号： US12664394申请日： 2008-08-06
-
公开(公告)号： US08293913B2公开(公告)日： 2012-10-23
- 发明人: Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Matthias Mayrer
- 申请人： Sean Colm Turner , Wilfried Braje , Andreas Haupt , Udo Lange , Karla Drescher , Karsten Wicke , Liliane Unger , Mario Mezler , Wolfgang Wernet , Andrea Hager-Wernet, legal representative , Matthias Mayrer
- 申请人地址： DE Wiesbaden
- 专利权人： Abbott GmbH & Co. KG
- 当前专利权人： Abbott GmbH & Co. KG
- 当前专利权人地址： DE Wiesbaden
- 代理机构： Michael Best & Friedrich LLP
- 代理商 Lisa V. Mueller
- 优先权： EP07113962 20070807
- 国际申请： PCT/EP2008/060335 WO 20080806
- 国际公布： WO2009/019286 WO 20090212
- 主分类号： C07D215/36
- IPC分类号： C07D215/36
摘要：
The present invention relates to novel quinoline compounds of the formula (I) and to the salts thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. In formula (I) R is a moiety of the formula (R) wherein * indicates the binding site to the quinolinyl radical and wherein A, B, X′, Y, Q, R1, R2, R3, R4, R5, m, n, p, q, Ra, Rb, X and Ar are as defined in claim 1.
公开/授权文献
信息查询
